Bio-Techne (TECH) Receivables Refunds (2010 - 2014)
Bio-Techne's quarterly Receivables Refunds came in at $4.2 million in Q4 2014, up 9.59% quarter-over-quarter from $3.8 million in Q1 2012.
Bio-Techne has reported Receivables Refunds for 3 years, with the latest figure at $4.2 million in Q4 2014.
- For the quarter ending Q4 2014, Receivables Refunds changed N/A year-over-year to $4.2 million; the trailing twelve-month figure through Dec 2014 stood at $4.2 million (changed N/A YoY), and the FY2010 full-year result was $1.8 million, changed N/A from the prior year.
- Receivables Refunds for Q4 2014 stood at $4.2 million, up from $3.8 million in the prior quarter.
- The five-year high for Receivables Refunds was $4.2 million in Q4 2014, with the low at $449000.0 in Q3 2010.
- Average Receivables Refunds over 3 years is $2.4 million, with a median of $1.8 million recorded in 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 4.18 Mn |
| Mar 31, 2012 | 3.82 Mn |
| Dec 31, 2010 | 1.67 Mn |
| Sep 30, 2010 | 449,000.00 |
| Jun 30, 2010 | 1.76 Mn |